George Kemble, Ph D.,
Vice-President of Research and Development, MedImmune Vaccines, Inc.
Date: March 22nd
Time: 6.30 pm -9.30 pm
Place: Crown Plaza Cabana, 4290 W. El Camino Real, Palo Alto, CA 94306, Tel: 650-628-0134
Abstract: Currently, avian H5N1 influenza viruses are spreading around the world exacting a toll on both human health as well as causing economic hardships. Recent advances in genetic techniques have allowed MedImmune to combine the attributes of its safe and effective FluMist® vaccine with antigens derived from a large number of avian influenza viruses. In collaboration with the National Institutes of Health, we are constructing and testing prototypic live, attenuated vaccines that may be used to prevent pandemic influenza. The progress toward developing and testing these important vaccines will be presented.
FluMist® was licensed for use in the U.S. 3 years ago and represents the most significant change to influenza vaccination technology in the past 50 years. This vaccine combines the genetic elements of a highly attenuated vaccine strain with antigenic components that match those of influenza strains that are causing current seasonal epidemics. The vaccine is administered by a fine nasal spray into the nose where it replicates and establishes an immune response. FluMist has been shown to effectively protect both children and adults from influenza disease.
Bio: George Kemble, PhD is currently Vice-President of Research and Development at MedImmune Vaccines, Inc. in Mountain View, CA. Dr. Kemble is a molecular virologist who received his PhD from Stanford University and continued his postdoctoral training at Univ. California, San Francisco. During his career in biotech, he has led programs to construct and clinically evaluate live, attenuated herpesvirus vaccines, as well as programs to develop and evaluate vaccines for important respiratory pathogens including influenza and respiratory syncytial virus.